Department of Pathology at MD Anderson Cancer Center, Houston, TX, USA.
The Johns Hopkins Hospital, Baltimore, MD, USA.
Hum Pathol. 2018 Mar;73:7-15. doi: 10.1016/j.humpath.2017.08.018. Epub 2017 Aug 26.
We present 1470 surgical resections for thymoma identified in the pathology files of 14 institutions from 11 countries with the purpose of determining and correlating a simplified histological classification of thymoma and pathological staging with clinical outcome. The study population was composed of 720 men and 750 women between the ages of 12 and 86 years (average, 54.8 years). Clinically, 137 patients (17%) had a history of myasthenia gravis, 31 patients (3.8%) of other autoimmune disease, and 55 (6.8%) patients of another neoplastic process. Surgical resection was performed in all patients. Histologically, 1284 (87.13%) cases were thymomas (World Health Organization types A, B1, and B2, and mixed histologies), and 186 (12.7%) were atypical thymomas (World Health Organization type B3). Of the entire group, 630 (42.9%) were encapsulated thymomas, and 840 (57.9%) were invasive thymomas in different stages. Follow-up information was obtained in 1339 (91%) patients, who subsequently were analyzed by univariate and multivariate statistical analysis. Follow-up ranging from 1 to 384 months was obtained (mean, 69.2 months) showing tumor recurrence in 136 patients (10.1%), whereas 227 died: 64 (28.2%) due to tumor and 163 (71.8%) due to other causes. Statistical analysis shows that separation of these tumors into thymoma and atypical thymoma is statistically significant (P = .001), whereas tumor staging into categories of encapsulated, minimally invasive, and invasion into adjacent organs offers a meaningful clinical assessment with a P = .038. Our findings suggest that our simplified histological schema and pathological staging system are excellent predictors of clinical outcome.
我们在 11 个国家的 14 家机构的病理档案中鉴定了 1470 例胸腺瘤手术切除标本,目的是确定和关联简化的胸腺瘤组织学分类和病理分期与临床结果。研究人群由 12 至 86 岁的 720 名男性和 750 名女性组成(平均年龄 54.8 岁)。临床上,137 例患者(17%)有重症肌无力病史,31 例患者(3.8%)有其他自身免疫性疾病史,55 例患者(6.8%)有其他肿瘤过程。所有患者均进行了手术切除。组织学上,1284 例(87.13%)为胸腺瘤(世界卫生组织 A、B1 和 B2 型及混合组织学),186 例(12.7%)为非典型胸腺瘤(世界卫生组织 B3 型)。在整个组中,630 例(42.9%)为包膜胸腺瘤,840 例(57.9%)为不同分期的侵袭性胸腺瘤。在 1339 例(91%)患者中获得了随访信息,随后对其进行了单因素和多因素统计分析。随访时间从 1 至 384 个月不等(平均 69.2 个月),显示 136 例患者(10.1%)肿瘤复发,而 227 例患者死亡:64 例(28.2%)死于肿瘤,163 例(71.8%)死于其他原因。统计分析表明,将这些肿瘤分为胸腺瘤和非典型胸腺瘤在统计学上是显著的(P =.001),而将肿瘤分期分为包膜、微创和侵袭到邻近器官的分类则提供了有意义的临床评估(P =.038)。我们的研究结果表明,我们简化的组织学分类和病理分期系统是临床结果的良好预测因子。